0.8616
price down icon2.45%   -0.0216
after-market After Hours: .87 0.0084 +0.97%
loading
Prelude Therapeutics Inc stock is traded at $0.8616, with a volume of 114.98K. It is down -2.45% in the last 24 hours and up +19.67% over the past month. Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$0.8832
Open:
$0.87
24h Volume:
114.98K
Relative Volume:
0.54
Market Cap:
$44.68M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.484
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
+6.37%
1M Performance:
+19.67%
6M Performance:
-44.41%
1Y Performance:
-77.74%
1-Day Range:
Value
$0.8342
$0.8914
1-Week Range:
Value
$0.78
$0.9499
52-Week Range:
Value
$0.6101
$6.80

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name
Name
Prelude Therapeutics Inc
Name
Phone
(302) 467-1280
Name
Address
175 INNOVATION BOULEVARD, WILMINGTON
Name
Employee
131
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
PRLD's Discussions on Twitter

Compare PRLD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRLD
Prelude Therapeutics Inc
0.8616 44.68M 0 -131.52M -107.56M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-19-24 Upgrade H.C. Wainwright Neutral → Buy
Jun-20-24 Downgrade Barclays Equal Weight → Underweight
Mar-13-24 Initiated JMP Securities Mkt Outperform
Feb-20-24 Downgrade H.C. Wainwright Buy → Neutral
Dec-19-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-21-22 Downgrade BofA Securities Neutral → Underperform
Sep-09-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-29-22 Initiated Jefferies Buy
Mar-15-22 Downgrade BofA Securities Buy → Neutral
Feb-28-22 Downgrade Barclays Overweight → Equal Weight
Oct-08-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-27-21 Upgrade BofA Securities Neutral → Buy
Apr-26-21 Initiated H.C. Wainwright Buy
Mar-09-21 Initiated Barclays Overweight
Nov-20-20 Downgrade BofA Securities Buy → Neutral
Oct-20-20 Initiated BofA Securities Buy
Oct-20-20 Initiated Goldman Neutral
Oct-20-20 Initiated Morgan Stanley Equal-Weight
View All

Prelude Therapeutics Inc Stock (PRLD) Latest News

pulisher
Apr 11, 2025

HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN

Apr 10, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo

Apr 02, 2025
pulisher
Apr 01, 2025

Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 29, 2025

Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo

Mar 29, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com India

Mar 28, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics stock surges on insider buying - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 26, 2025

PRLD stock touches 52-week low at $0.66 amid sharp annual decline - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ - openPR.com

Mar 25, 2025
pulisher
Mar 24, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock - Investing.com India

Mar 24, 2025
pulisher
Mar 22, 2025

Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MyChesCo

Mar 22, 2025
pulisher
Mar 19, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

Prelude Therapeutics’ SWOT analysis: biotech stock faces mixed outlook amid clinical trials - Investing.com Australia

Mar 17, 2025
pulisher
Mar 16, 2025

NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial - MyChesCo

Mar 16, 2025
pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares - Investing.com

Mar 14, 2025
pulisher
Mar 13, 2025

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements - MyChesCo

Mar 13, 2025
pulisher
Mar 12, 2025

Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD) - The Globe and Mail

Mar 12, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Increases Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - The AM Reporter

Mar 11, 2025
pulisher
Mar 11, 2025

Prelude Therapeutics Reports 2024 Financial Results - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Inc SEC 10-K Report - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MyChesCo

Mar 09, 2025
pulisher
Mar 07, 2025

Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo

Mar 07, 2025
pulisher
Mar 06, 2025

Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo

Mar 05, 2025
pulisher
Mar 05, 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo

Mar 05, 2025
pulisher
Mar 04, 2025

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance

Mar 04, 2025
pulisher
Feb 28, 2025

Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN

Feb 28, 2025
pulisher
Feb 27, 2025

PRLD stock touches 52-week low at $0.79 amid market challenges - Investing.com

Feb 27, 2025

Prelude Therapeutics Inc Stock (PRLD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Cap:     |  Volume (24h):